When customers talk about AI costs, the conversation usually starts with token prices and ends with access to the latest, most capable model in the cloud. Do they always need that level of capability? Not necessarily. But that is often where the conversation goes.
As AI moves from experimenta...
Vaccines that turn the body’s immune system against tumors have shown promise in clinical trials, and a handful have been FDA approved for certain cancers. In many patients, however, these vaccines don’t stimulate enough of a response, and the approach some researchers have taken to strengthening it...
The AI boom is becoming a materials challenge. As AI pushes computing into new territory, the materials behind that infrastructure are becoming just as crucial as the algorithms running on it. Semiconductors and data centers are approaching physical limits around performance, thermal management, ele...
For many small-to-medium-sized businesses (SMBs), VMware has become too expensive.
Broadcom’s acquisition of the virtualization firm brought the end of perpetual license sales and the arrival of pricey, stacked, subscription-based bundles that priced out many SMBs.
The most obvious is VMware Cloud F...